SPL028 is a proprietary deuterated DMT candidate with multi-layered IP protection Phase I study will compare two routes of SPL028 administration; intravenous and intramuscular LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health…